Novartis Ag (NVS) Operating Income Growth (1y) (2010 - 2025)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Op. Inc Growth (1y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
80.35% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
2.93% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
6.88% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-411.15% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
126.32% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
15.60% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-0.98% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
-193.55% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Jun 30, 2025 |
21.18% |
| Dec 31, 2024 |
36.17% |
| Jun 30, 2024 |
-30.51% |
| Dec 31, 2023 |
1,887.18% |
| Jun 30, 2023 |
23.26% |
| Mar 31, 2023 |
-19.04% |
| Dec 31, 2022 |
-29.27% |
| Sep 30, 2022 |
-14.32% |
| Jun 30, 2022 |
-16.05% |
| Mar 31, 2022 |
26.28% |
| Dec 31, 2021 |
3.76% |
| Sep 30, 2021 |
11.39% |
| Jun 30, 2021 |
8.58% |
| Mar 31, 2021 |
793.33% |
| Mar 31, 2020 |
-116.48% |
| Mar 31, 2019 |
-33.25% |
| Dec 31, 2018 |
-22.30% |
| Sep 30, 2018 |
-8.21% |
| Jun 30, 2018 |
8.95% |
| Mar 31, 2018 |
19.24% |
| Dec 31, 2017 |
-95.95% |
| Sep 30, 2017 |
10.17% |
| Jun 30, 2017 |
500.00% |
| Mar 31, 2017 |
99,132,847.98% |
| Dec 31, 2016 |
3,387.96% |
| Sep 30, 2016 |
91,237,113,401,961.88% |
| Mar 31, 2016 |
1.76% |
| Dec 31, 2015 |
59,177,982.19% |
| Sep 30, 2015 |
-100.00% |
| Mar 31, 2015 |
-49.55% |
| Sep 30, 2012 |
5.57% |
| Jun 30, 2012 |
12.94% |
| Mar 31, 2012 |
-30.73% |
| Dec 31, 2011 |
167.86% |
| Sep 30, 2011 |
-20.70% |
| Jun 30, 2011 |
26.19% |
| Mar 31, 2011 |
-85.08% |
| Dec 31, 2010 |
-97.31% |
| Sep 30, 2010 |
-83.68% |
| Jun 30, 2010 |
8.49% |
| Mar 31, 2010 |
49.60% |
